ArriVent reports Q3 net loss $130.8M; cash $305.4M funds into mid-2027

ArriVent BioPharma, Inc.

2025-Q3 EPS reported -$3.54 vs consensus -$0.81 ▼ miss (-339.7%)

Net loss $130.8M for nine months ended Sep 30, 2025, up from $59.9M in 2024, driven by R&D spend including $40M upfront for ARR-217.
Cash and investments $305.4M as of Sep 30, 2025; expected to fund operations into mid-2027.
R&D expense $121.2M (incl. $40M upfront for ARR-217 license) vs $58.8M prior year; G&A $17.5M vs $11.8M.
Appointed Brent S. Rice as Chief Commercial Officer; Phase 1b firmonertinib data in EGFR PACC mutant NSCLC presented at WCLC.
Phase 3 ALPACCA trial for PACC mutant NSCLC first patient enrollment expected Q4 2025; topline FURVENT Phase 3 data in exon 20 insertion NSCLC projected early 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.